Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBT (2021 - 2025)

Kiniksa Pharmaceuticals International's EBT history spans 5 years, with the latest figure at -$62.8 million for Q4 2025.

  • For Q4 2025, EBT fell 646.34% year-over-year to -$62.8 million; the TTM value through Dec 2025 reached $2.8 million, up 136.16%, while the annual FY2025 figure was $2.8 million, 136.16% up from the prior year.
  • EBT reached -$62.8 million in Q4 2025 per KNSA's latest filing, down from $27.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $128.2 million in Q4 2021 to a low of -$62.8 million in Q4 2025.
  • Average EBT over 5 years is $8.6 million, with a median of -$4.2 million recorded in 2023.
  • The largest YoY upside for EBT was 892.93% in 2025 against a maximum downside of 646.34% in 2025.
  • A 5-year view of EBT shows it stood at $128.2 million in 2021, then fell by 29.11% to $90.9 million in 2022, then grew by 2.94% to $93.6 million in 2023, then plummeted by 87.71% to $11.5 million in 2024, then plummeted by 646.34% to -$62.8 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's EBT are -$62.8 million (Q4 2025), $27.2 million (Q3 2025), and $22.9 million (Q2 2025).